Selling a Hospice in Arizona: A 2026 Owner’s Guide

On May 13, 2026, CMS froze new hospice and home health enrollments across the country, and Arizona sits at the center of the story that prompted it. For the owner of a clean, established Arizona hospice, that freeze is not only a headline about fraud. It is a market signal. If no one can stand up a new competing license right now, a legitimate, seasoned Arizona hospice becomes a scarcer and more valuable asset. This guide explains how selling a hospice in Arizona actually works in 2026, what your hospice is worth, how the moratorium and the 36-month ownership rule shape the timing, and how to prepare so you negotiate from a position of strength.

As of July 2026, the market rewards owners who can prove their hospice is real, compliant, and durable. The CMS enrollment moratorium is a six-month, nationwide pause, and Arizona is one of four states, with California, Nevada, and Texas, flagged for heightened oversight. That scrutiny raises the bar in diligence, but it also thins the field of buyers who can grow by opening new locations. The result is a narrower, more selective market where preparation is the difference between a repriced deal and a strong one.

Can you sell a hospice in Arizona during the CMS moratorium?

Yes, you can sell a hospice in Arizona during the 2026 moratorium in many deal structures, but not in every one. The moratorium blocks new initial Medicare enrollments and blocks a change in majority ownership when a hospice seeks that change within 36 months of its initial enrollment. A sale that does not require a new initial enrollment, and that involves a hospice already past its first 36 months, can generally proceed. The structure of your transaction, not just the decision to sell, is what determines whether the freeze applies.

CMS decides whether a deal is a true change of ownership or a lesser change of information based on operational control, not on how the paperwork is labeled. That is why Arizona owners should map the deal structure early with advisors who understand hospice enrollment rules. The moratorium is authorized under Section 1866(j)(7) of the Social Security Act and 42 C.F.R. 424.570, and CMS has said it may extend the pause in additional six-month increments. Planning around that uncertainty is part of running a smart process this year.

Why is Arizona under extra hospice scrutiny?

Arizona is under extra scrutiny because it saw one of the fastest hospice provider expansions in the country, and regulators concluded a share of that growth was driven by fraud rather than patient need. In its March 2026 report to Congress, MedPAC reported that Arizona added 96 hospice providers between 2019 and 2023, a 14% average annual increase, with only California, Texas, and Nevada posting similarly elevated growth. Much of that expansion landed in areas that did not need more hospices.

The pattern behind the numbers is what drew enforcement. Some new hospices obtained licenses only to sell them to other operators. Others billed Medicare for patients who did not exist or who were not eligible. CMS responded with a Special Focus Program for poor performers, a rule forbidding a change in majority ownership during the first 36 months after initial enrollment, heightened oversight in Arizona and three peer states, and payment suspensions that have withheld roughly $1.4 billion from providers in recent enforcement. For a legitimate Arizona owner, the takeaway is straightforward: buyers and regulators now assume nothing, so your ability to document a clean, real operation is your strongest advantage.

What is an Arizona hospice worth in 2026?

As of July 2026, most quality hospices trade in a range of about 5.0x to 9.0x adjusted EBITDA, with the exact multiple depending on size, compliance history, census stability, length of stay, cap exposure, and referral durability. Independent advisory data puts small independent hospices (revenue under $5M) around 3.0x to 6.0x, regional operators ($5M to $30M) around 6.0x to 10.0x, and exceptional platforms with geographic density and clean compliance above 9.0x, reaching into the low teens. Hospice valuations have been ticking upward through 2026 as deal volume rebounds.

Hospice profile	Typical 2026 EBITDA multiple	What drives the range
Small independent (revenue under $5M)	3.0x to 6.0x	Higher operational risk, limited reach, owner dependence
Regional operator ($5M to $30M)	6.0x to 10.0x	Scale, market density, service mix, cash-flow stability
Scaled platform, clean compliance	9.0x and above	Density, quality metrics, diversified referrals, documentation

Two Arizona-specific factors sit on top of those bands in 2026. First, scarcity: with the moratorium blocking new licenses, an established, compliant Arizona hospice is harder to replicate, which supports value for clean operators. Second, risk: because Arizona is a flagged state, buyers price in the cost of proving your census, discharges, and billing hold up under enhanced review. A number you read in a report is not an offer. Two Arizona hospices with identical EBITDA can be several turns apart on price because one has clean diligence and the other does not. Reimbursement context matters too. The FY2026 hospice aggregate cap is $35,361.44, and cap exposure is a core part of how buyers underwrite go-forward earnings.

How does the 36-month rule affect selling an Arizona hospice?

The 36-month rule forbids a change in majority ownership during the first 36 months after a hospice’s initial Medicare enrollment, and in 2026 it works alongside the moratorium to shape when and how you can sell. If your hospice enrolled more than 36 months ago, the rule is generally not an obstacle, and a well-structured sale can move forward. If your hospice is younger than 36 months, a majority ownership change is restricted, and the current moratorium reinforces that restriction. This is the single most important date for many Arizona sellers to confirm before going to market.

The rule applies to acquisitions, stock transactions, and mergers that transfer majority ownership, which is why deal structure and timing are worth planning early. An owner who is a year into enrollment has different options than one who is five years in, and an advisor can help sequence a transaction so it does not accidentally trigger a new initial enrollment during the freeze. For most established Arizona hospices, the rule is a planning input, not a wall. For newer ones, it is a reason to prepare now and time the process correctly rather than rushing into a structure that CMS will not allow.

What do buyers check when acquiring an Arizona hospice?

Buyers acquiring an Arizona hospice in 2026 underwrite compliance and clinical integrity first, then earnings quality: live discharge rate, average length of stay, cap exposure, documentation, survey history, and referral durability. Hospice-specific risk gets sharper scrutiny than in other verticals because the fraud enforcement is hospice-led. A buyer wants to see that your patients are eligible, your discharges are clinically appropriate, and your billing would survive an audit. In a flagged state, that proof is not a formality. It is the deal.

Live discharge is the metric drawing the most attention. April 2026 Qlarant suspension letters leaned on live discharge rates ranging from the mid-50% range up to 64%, against a national non-death discharge rate of roughly 17% to 18%. A rate near the national norm signals a real, well-run hospice. A high rate invites questions. Length of stay matters for the opposite reason: a national average around 90 days, with a healthy operation often in the 90 to 180 day band, points to genuine referral relationships and predictable revenue, while very short stays can signal churn. The table below shows how these drivers move an Arizona hospice’s value in opposite directions.

Value driver	Raises your multiple	Lowers your multiple
Live discharge rate	Near or below the national norm (about 17% to 18%)	Elevated (the 50%+ range that triggers scrutiny)
Average length of stay	Healthy band (about 90 to 180 days)	Very short-stay churn or unexplained long stays
Compliance	Clean surveys, no SFP flag, no open audits	Survey deficiencies, audits, program-integrity flags
Cap exposure	Managed and understood (FY2026 cap $35,361.44)	Near or over cap with liability risk
Referral sources	Diversified facilities and physicians, transferable	Concentrated or tied to the owner personally
Documentation	Eligibility, certifications, and encounters in order	Gaps that cannot survive an audit

How do I prepare an Arizona hospice for sale?

Preparing an Arizona hospice for sale means confirming your enrollment date against the 36-month rule, cleaning up compliance and clinical documentation, right-sizing live discharge and length-of-stay patterns, managing cap exposure, and organizing financials before a buyer ever asks. In a flagged state, the goal is to make your hospice easy to verify. The steps below are the same ones a buyer and their diligence team will grade you against, and most owners benefit from starting them 3 to 6 months before going to market.

Eight steps to prepare an Arizona hospice for sale

1. Confirm your 36-month enrollment date. Know exactly when your hospice enrolled in Medicare so you can structure the deal and timing correctly under the current rules.
2. Clean up clinical documentation. Make sure eligibility, certifications, and face-to-face encounters are complete and audit-ready.
3. Review live discharge patterns. Understand your rate versus the national norm and be ready to explain any variance with clinical rationale.
4. Check length of stay and census mix. Confirm your ALOS sits in a defensible band and that referrals are diversified, not owner-dependent.
5. Manage cap exposure. Model your position against the FY2026 cap of $35,361.44 and address any liability before diligence.
6. Organize buyer-ready financials. Move to clean, monthly financials and document add-backs so a Quality of Earnings review can confirm them.
7. Resolve compliance items. Close out survey deficiencies, confirm you are not on the Special Focus Program list, and tidy billing.
8. Get a confidential valuation and run a process. Know your range before you negotiate, and let an advisor create competition among qualified, vetted buyers.

Should I sell my Arizona hospice now or wait?

Whether to sell now or wait depends on your enrollment date, your compliance readiness, and your personal timeline, not on any single headline. For a clean, established Arizona hospice, 2026 has real advantages: the moratorium limits new competition, valuations are ticking upward, and buyers who cannot open new locations are more motivated to acquire proven ones. If your documentation, discharges, length of stay, and cap position are in order, a scarcer market is a reasonable moment to explore your options.

Waiting has trade-offs in both directions. Wait too long and you risk a survey finding, a program-integrity flag, or a reimbursement change that erases value. Move before you are ready and you negotiate from weakness in a state where buyers assume they must verify everything. The way through is to get a current valuation, understand your gaps, and decide with numbers in front of you. For a broader view of how hospice value is set this year, see our 2026 hospice and home health valuation multiples report and our overview of the seven steps to selling.

Is selling right for every Arizona hospice owner?

Selling is not the right move for every Arizona hospice owner, and a good advisor will tell you when a strategic buyer, a recapitalization, or staying independent is the better fit. Selling tends to suit owners who want meaningful liquidity now, who are comfortable with new ownership and reporting discipline, or who see the current scarcity as a window worth using. A recapitalization can let you take value off the table while keeping a stake and a role. Staying independent can make sense if your hospice is young under the 36-month rule and you would rather build first.

Whatever the path, confidentiality protects your value. Staff, referral sources, and competitors should not learn you are exploring a sale until you choose to tell them, which matters even more in a tight Arizona market where word travels. A disciplined process, run under non-disclosure agreements with qualified buyers only, keeps your operation stable while you evaluate offers. Anonymous buyer demand can be tested through platforms like Exits.ai, and timing and succession questions are worth working through with ExitStrategies.com.

Frequently asked questions

Does the CMS moratorium mean I cannot sell my Arizona hospice at all?

No. The moratorium blocks new initial enrollments and majority ownership changes within 36 months of enrollment, but many sales of established Arizona hospices can still be structured to proceed. What matters is whether your specific deal requires a new initial enrollment, which is a structuring question to work through early.

How long does it take to sell a hospice in Arizona?

A typical hospice sale runs several months from engagement to closing, with roughly 3 to 6 months of preparation before that. In a flagged state like Arizona, clean documentation shortens diligence and messy records extend it, so preparation is the biggest lever on your timeline.

What multiple will my Arizona hospice sell for?

Most quality hospices trade around 5.0x to 9.0x adjusted EBITDA in 2026, with smaller independents lower and scaled, compliant platforms higher. Your Arizona hospice’s multiple depends on compliance history, live discharge, length of stay, cap exposure, and referral durability, so no single number applies without diligence.

Why does live discharge rate matter so much to buyers?

Live discharge rate is a leading indicator regulators use to spot possible fraud or ineligible admissions. With national non-death discharge around 17% to 18% and recent suspension letters citing rates above 50%, a normal rate reassures buyers that your census is real and your value is durable.

Is my Arizona hospice more or less valuable because of the crackdown?

For a clean, established hospice, the crackdown can support value, because the moratorium limits new competition and buyers cannot simply open a new license. The offset is heavier diligence. Owners who can prove compliance and clinical integrity are positioned best in this market.

What is the FY2026 hospice cap and why does it matter?

The FY2026 aggregate cap is $35,361.44 per beneficiary. It limits total Medicare payment per patient on average, so buyers review your cap position closely. Being near or over the cap creates liability that can reduce your price or complicate a deal.

How do I keep a sale confidential in a small Arizona market?

Confidentiality is maintained by running a structured process under non-disclosure agreements, disclosing your identity only to qualified, vetted buyers, and controlling what information is shared and when. This protects your relationships with staff, referral sources, and competitors while you evaluate offers.

About the author

Jason Atty is the founder of Vallexa Advisors, a healthcare-only M&A advisory firm that helps hospice, home health, and home care owners understand value, prepare intelligently, and run confidential sale processes that attract qualified buyers. Vallexa works on 100% success-based fees, with a healthcare-only focus, a confidentiality-first approach, and a nationwide buyer network. The firm advises owners across the home-based care spectrum on valuation, preparation, and exit strategy. As of July 2026, Vallexa continues to track hospice M&A activity, CMS enforcement and enrollment rules, and buyer demand in Arizona and other flagged states to help owners time and structure their decisions.

Related resources

• Hospice M&A advisory
• 2026 hospice valuation multiples report
• Business valuation calculator
• The 7 steps to selling
• Anonymous buyer mandates (Exits.ai)

Educational only. Not legal, financial, or tax advice. Healthcare M&A outcomes depend on specific facts, payer mix, market conditions, and regulatory context. Speak with qualified counsel before acting on anything in this document.

Sources: CMS, Six-Month Hospice and Home Health Enrollment Moratoria press release (May 2026); CMS FY2026 Hospice Wage Index Final Rule fact sheet (CMS-1835-F); MedPAC March 2026 Report to Congress, Hospice chapter; ProPublica, Hospices in Four States to Receive Extra Scrutiny (2024); Hospice News, Hospice M&A Valuations Ticking Upward (2026).

Estimated reading time: 13 minutes

CMS Freezes New Hospice and Home Health Enrollment Nationwide: What the Six-Month Moratorium Means for Owners, Buyers, and Valuations

Comprehensive Guide to Selling Senior Healthcare Businesses: Assisted Living, Hospice, Home Health & More